MedPath

Ethniq Launches Patented Natural Antifungal Treatment Showing 90% Efficacy in Clinical Trials

3 months ago3 min read

Key Insights

  • Ethniq has launched Skin Revive, a patented steroid-free treatment for chronic fungal skin infections that demonstrated over 90% efficacy in clinical trials registered with CTRI.

  • The natural formulation combines almond extract, coconut oil, eucalyptus oil, and chamomile processed through special extraction methods and has received patents in India and internationally.

  • The treatment addresses a significant medical need as fungal infections affect up to 61% of the population in some Indian states, with conventional steroid-based treatments facing growing drug resistance concerns.

Ethniq, a natural medicine company, has introduced Skin Revive, a patented steroid-free treatment for chronic fungal skin infections that demonstrated over 90% efficacy in clinical trials. The launch addresses a growing medical challenge as fungal infections become increasingly resistant to conventional treatments across India.

Addressing a Significant Medical Need

According to the Indian Association of Dermatologists, Venereologists and Leprologists (IADVL), fungal infections such as dermatophytosis affect up to 61% of the population in some Indian states, with cases surging during humid monsoon months. Conventional treatments often rely on steroid-laden creams that carry risks of relapse and drug resistance, presenting a growing concern among dermatologists.
"This is the first time a patented natural cure for fungal skin infections has been brought to market," said Tajinder Virk, co-founder of Ethniq. "We built Ethniq to deliver solutions where conventional medicine were not fully effective by combining the wisdom of food-based remedies with rigorous clinical science."

Patented Natural Formulation

Skin Revive's formula, which has been granted patents in India and internationally for its unique composition and mode of action, combines almond extract, coconut oil, eucalyptus oil, and chamomile. The ingredients are processed through special temperature and pressure extraction methods designed to preserve full therapeutic potency.
The treatment was developed by Dr. Sunita Kumari, one of the inventors named on the patent. The product is AYUSH-certified, GMP-manufactured, and tested for broad-spectrum fungal resistance. Unlike standard antifungals that often mask symptoms, Skin Revive aims to eliminate the root cause of fungal overgrowth without the risks associated with steroids.

Clinical Evidence and Therapeutic Approach

Clinical trials registered with CTRI demonstrated the treatment's over 90% efficacy rate. "Our clinical results show clear, sustained improvement in cases that had failed on conventional therapies," said Dr. Sunita Kumari.
The therapeutic approach represents a departure from conventional antifungal treatments by targeting the underlying causes of fungal overgrowth rather than merely addressing surface symptoms. This mechanism aims to provide sustained improvement while avoiding the complications associated with steroid-based treatments.

Company Background and Future Pipeline

Ethniq was founded by Tajinder Virk, Dr. Rajoria, and Dr. Ankit Vatsyayan to apply scientific rigor to India's traditional food-based healing practices. The company positions itself as bridging ancient food-based healing traditions with modern clinical science to create natural remedies that are both effective and transparent.
Skin Revive represents the company's debut product, with additional innovations currently in development. The treatment is available in 10ml and 30ml formats, offering a clinically proven option for patients seeking natural solutions to chronic fungal skin infections as drug resistance continues to spread across India.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.